Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon α2a (40 kDa; PEGASYS®)

Antiviral Therapy

Volumn 13, Issue 4, 2008, Pages 555-562

  Chan, Henry L Y ^a   Wong, Vincent W S ^a   Chim, Angel M L ^a   Wong, Grace L H ^a   Chan, Hoi Yun ^a   Sung, Joseph J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA;

ADULT; ALOPECIA; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GINGIVA BLEEDING; HEPATITIS B; HUMAN; HUMAN CELL; HYPOTHYROIDISM; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING; UPPER RESPIRATORY TRACT INFECTION; VIRUS DETECTION;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 47649100635     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
2. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26:177-182.
3. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32:803-806.
4. van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52:420-424.
5. Lee KM Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9:208-212.
6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
7. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25:472-489.
8. Keeffe EB, Dieterich DT, Han SH, et al. A treatment of algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006; 4:936-962.
9. Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12:345-353.
10. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758.
11. Sung JJY, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128:1890-1897.
12. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142:240-250.
13. Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365:123-129.
14. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
15. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
16. Hui AY, Chan HL, Cheung A, Cooksley G, Sung JJ. Treatment of chronic hepatitis B virus infection by pegylated interferon: systematic review of 4 randomized studies. Aliment Pharmacol Ther 2005; 22:519-528.
17. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41:1357-1364.
18. Marcellin P, Bonino F, Lau GK, et al. Suppression of HBV DNA in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (40KD) ±lamivudine: 2-year follow-up results. 57th Annual Meeting of the American Association for the Study of Liver Diseases. 27-31 October 2006, Boston, MA, USA. Abstract 972.
19. Chan HL, Wong VW, Chim AM, et al. Virological response to different combination regimes of peginterferon alfa-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther 2007; 12:815-823.
20. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44:675-684.
21. Flink HJ, Hansen BE, Heathcote EJ, et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol 2006; 101:2523-2529.
22. Chan HL, Chui AK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68:182-187.
23. Loeb KR, Jerome KR, Goddard J, Huang ML, Cent A, Corey L. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 2000; 32:626-629.
24. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographical origin of hepatitis B virus - largescaled analysis using a new genotyping method. J Infect Dis 1997; 175:1285-1293.
25. Chan HL, Tsang SW, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histologic liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97:406-412.
26. Hussain M, Fung S, Libbrecht E, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006; 44:1094-1097.
27. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viraemia? Hepatology 2001; 34:1021-1026.
28. Chan HL, Wong VW, Hui AY, et al. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther 2006; 11:465-471.
29. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5:1462-1468.
30. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5:890-897.
31. Lai CL, Gane E, Liaw TF, et al. Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (The GLOBE Study). 56th Annual Meeting of American Association for the Study of Liver Diseases. 11-15 November 2005, Boston, MA, USA. Abstract 92.
32. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). 40th Annual Meeting of European Association for the Study of the Liver. 13-17 April 2005, Paris, France. Abstract 36.
33. Chan HL, Wong VW, Tse CH, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007; 25:891-898.
34. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36 Suppl 1:S145-S151.